NZ600478A - Beta-carbolines for use in the treatment of hearing loss and vertigo - Google Patents
Beta-carbolines for use in the treatment of hearing loss and vertigoInfo
- Publication number
- NZ600478A NZ600478A NZ600478A NZ60047810A NZ600478A NZ 600478 A NZ600478 A NZ 600478A NZ 600478 A NZ600478 A NZ 600478A NZ 60047810 A NZ60047810 A NZ 60047810A NZ 600478 A NZ600478 A NZ 600478A
- Authority
- NZ
- New Zealand
- Prior art keywords
- carboline
- vertigo
- methyl
- trauma
- carbolines
- Prior art date
Links
- 208000012886 Vertigo Diseases 0.000 title abstract 4
- 231100000889 vertigo Toxicity 0.000 title abstract 4
- 206010011878 Deafness Diseases 0.000 title abstract 3
- 208000016354 hearing loss disease Diseases 0.000 title abstract 3
- 231100000888 hearing loss Toxicity 0.000 title abstract 2
- 230000010370 hearing loss Effects 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 title abstract 2
- 208000014674 injury Diseases 0.000 abstract 3
- 230000008733 trauma Effects 0.000 abstract 3
- 208000027601 Inner ear disease Diseases 0.000 abstract 2
- 208000027530 Meniere disease Diseases 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 2
- 210000003027 ear inner Anatomy 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 208000027491 vestibular disease Diseases 0.000 abstract 2
- 206010011903 Deafness traumatic Diseases 0.000 abstract 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 abstract 1
- 208000009205 Tinnitus Diseases 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 231100000895 deafness Toxicity 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004880 explosion Methods 0.000 abstract 1
- 238000002513 implantation Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 231100000886 tinnitus Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102009060811 | 2009-12-28 | ||
| US28239510P | 2010-02-02 | 2010-02-02 | |
| PCT/DE2010/001530 WO2011079841A1 (de) | 2009-12-28 | 2010-12-28 | Beta-carboline zur behandlung von hörschäden und schwindel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ600478A true NZ600478A (en) | 2013-10-25 |
Family
ID=44246908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ600478A NZ600478A (en) | 2009-12-28 | 2010-12-28 | Beta-carbolines for use in the treatment of hearing loss and vertigo |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9107914B2 (enExample) |
| EP (1) | EP2519238B1 (enExample) |
| JP (1) | JP5627705B2 (enExample) |
| KR (1) | KR20120098855A (enExample) |
| CN (1) | CN102844029A (enExample) |
| AU (1) | AU2010338669A1 (enExample) |
| BR (1) | BR112012015967B1 (enExample) |
| CA (1) | CA2785233C (enExample) |
| DE (1) | DE112010005017A5 (enExample) |
| IL (1) | IL220661A (enExample) |
| IN (1) | IN2012DN05066A (enExample) |
| MX (1) | MX2012007678A (enExample) |
| NZ (1) | NZ600478A (enExample) |
| RU (1) | RU2012132429A (enExample) |
| SG (1) | SG181599A1 (enExample) |
| WO (1) | WO2011079841A1 (enExample) |
| ZA (1) | ZA201204476B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3184040A1 (en) | 2013-03-14 | 2014-10-02 | The Brigham And Women's Hospital, Inc. | Compositions and methods for epithelial stem cell expansion comprising a wnt agonist and a histone deacetylase inhibitor |
| DK2968284T3 (da) | 2013-03-14 | 2021-06-14 | Osteoqc Inc | Alkyl-amin-harminderivater til fremme af knoglevækst |
| EP2853533A1 (de) * | 2013-09-29 | 2015-04-01 | Audiocure Pharma GmbH | 6-Fluor-9-methyl-ß-carbolin |
| WO2016037016A1 (en) | 2014-09-03 | 2016-03-10 | The Brigham And Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
| AU2017205194A1 (en) | 2016-01-08 | 2018-07-19 | Massachusetts Institute Of Technology | Production of differentiated enteroendocrine cells and insulin producing cells |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| EP3321264A1 (en) * | 2016-11-14 | 2018-05-16 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways |
| CN110392686A (zh) | 2016-12-30 | 2019-10-29 | 频率治疗公司 | 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法 |
| CN112996506A (zh) | 2018-08-14 | 2021-06-18 | 奥斯特克有限公司 | 吡咯并二吡啶化合物 |
| BR112021002655A2 (pt) | 2018-08-14 | 2021-05-04 | Osteoqc Inc. | compostos flúor ss-carbolina |
| WO2020037326A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
| US11162071B2 (en) | 2018-08-17 | 2021-11-02 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating JAG-1 |
| EP3849530A4 (en) * | 2018-09-12 | 2022-06-22 | Hough Ear Institute | Methods for treating hearing loss incident to cochlear implant surgery |
| EP3772515A1 (en) * | 2019-08-09 | 2021-02-10 | Audiocure Pharma GmbH | Stable polymorphic form of 6-fluoro-9-methyl-9h-ss-carboline and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3240514A1 (de) | 1982-10-29 | 1984-05-03 | Schering AG, 1000 Berlin und 4709 Bergkamen | Ss-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
| US20040038970A1 (en) | 1998-06-12 | 2004-02-26 | Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. | Beta-carboline compounds |
| CN1169808C (zh) * | 1998-06-12 | 2004-10-06 | 研究及应用科学协会股份有限公司 | β-咔啉化合物 |
| US20050143371A1 (en) * | 2003-07-23 | 2005-06-30 | Pharmacia Corporation | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
| DE102007009264A1 (de) | 2007-02-26 | 2008-08-28 | Ellneuroxx Ltd. | 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen |
-
2010
- 2010-12-28 CA CA2785233A patent/CA2785233C/en active Active
- 2010-12-28 DE DE112010005017T patent/DE112010005017A5/de not_active Withdrawn
- 2010-12-28 AU AU2010338669A patent/AU2010338669A1/en not_active Abandoned
- 2010-12-28 SG SG2012042438A patent/SG181599A1/en unknown
- 2010-12-28 BR BR112012015967A patent/BR112012015967B1/pt active IP Right Grant
- 2010-12-28 KR KR1020127017073A patent/KR20120098855A/ko not_active Withdrawn
- 2010-12-28 NZ NZ600478A patent/NZ600478A/xx unknown
- 2010-12-28 JP JP2012546361A patent/JP5627705B2/ja active Active
- 2010-12-28 EP EP10812791.1A patent/EP2519238B1/de active Active
- 2010-12-28 WO PCT/DE2010/001530 patent/WO2011079841A1/de not_active Ceased
- 2010-12-28 US US13/514,171 patent/US9107914B2/en active Active
- 2010-12-28 MX MX2012007678A patent/MX2012007678A/es not_active Application Discontinuation
- 2010-12-28 RU RU2012132429/04A patent/RU2012132429A/ru not_active Application Discontinuation
- 2010-12-28 CN CN2010800630256A patent/CN102844029A/zh active Pending
-
2012
- 2012-06-07 IN IN5066DEN2012 patent/IN2012DN05066A/en unknown
- 2012-06-18 ZA ZA2012/04476A patent/ZA201204476B/en unknown
- 2012-06-26 IL IL220661A patent/IL220661A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP2519238A1 (de) | 2012-11-07 |
| CN102844029A (zh) | 2012-12-26 |
| KR20120098855A (ko) | 2012-09-05 |
| CA2785233A1 (en) | 2011-06-07 |
| CA2785233C (en) | 2018-10-09 |
| ZA201204476B (en) | 2014-01-29 |
| MX2012007678A (es) | 2012-09-12 |
| SG181599A1 (en) | 2012-07-30 |
| BR112012015967A2 (pt) | 2016-04-19 |
| EP2519238B1 (de) | 2014-08-13 |
| US20130028958A1 (en) | 2013-01-31 |
| BR112012015967B1 (pt) | 2019-08-27 |
| IN2012DN05066A (enExample) | 2015-10-09 |
| JP5627705B2 (ja) | 2014-11-19 |
| RU2012132429A (ru) | 2014-02-10 |
| WO2011079841A1 (de) | 2011-07-07 |
| AU2010338669A1 (en) | 2012-06-21 |
| IL220661A0 (en) | 2012-08-30 |
| JP2013515752A (ja) | 2013-05-09 |
| IL220661A (en) | 2016-03-31 |
| DE112010005017A5 (de) | 2012-10-04 |
| US9107914B2 (en) | 2015-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ600478A (en) | Beta-carbolines for use in the treatment of hearing loss and vertigo | |
| ZA200810113B (en) | Method for the treatment and prevention of ocular disorders | |
| MX2010002617A (es) | Implantes lagrimales y metodos relacionados. | |
| JO3032B1 (ar) | مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية. | |
| IL212113A (en) | A device for the implantation of a drug for glaucoma treatment | |
| MX2013001204A (es) | Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares. | |
| UA115320C2 (uk) | Інгібітори кінази | |
| UA105781C2 (uk) | Низькомолекулярне полісульфатоване похідне гіалуронової кислоти і лікарський засіб, який його містить | |
| PH12012501021A1 (en) | Indole compound and pharmaceutical use thereof | |
| NZ602510A (en) | Treatment of lupus nephritis using laquinimod | |
| MX2010009623A (es) | Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| NZ597626A (en) | Bicyclic compound and use thereof for medical purposes | |
| MX2011011109A (es) | Formulaciones orales de bendamustina. | |
| MX2010009625A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| PH12014500967A1 (en) | A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent | |
| MX2012000136A (es) | Composiciones que comprenden finafloxacina y metodos para tratar infecciones oftalmicas, oticas, o nasales. | |
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| NZ597030A (en) | Method for treatment of diseases | |
| WO2010132352A3 (en) | Spiro compounds and their use as therapeutic agents | |
| MX2010010455A (es) | Formas solidas de un compuesto fosfoindol anti-vih. | |
| MX2013002956A (es) | Arilsulfonamidas para el tratamiento de enfermedades del sistema nervioso central. | |
| WO2007035121A3 (en) | Isoflavones for treating mucopolysaccharidoses | |
| MX356814B (es) | Métodos y composiciones para neuroprotección. | |
| EP4494704A3 (en) | Use of cyclic amide derivatives to treat sleep disorders | |
| RU2010135224A (ru) | Способ хирургического лечения макулярного отека после факоэмульсификации катаракты |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2015 BY PAVIS EG Effective date: 20141212 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2016 BY PAVIS EG Effective date: 20151210 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2017 BY PAVIS EG Effective date: 20161219 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2018 BY PAVIS GMBH Effective date: 20171215 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2019 BY PAVIS GMBH Effective date: 20181218 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2020 BY PAVIS GMBH Effective date: 20191220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2021 BY PAVIS PAYMENTS GMBH Effective date: 20201223 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2022 BY PAVIS GMBH Effective date: 20211216 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2023 BY PAVIS PAYMENTS GMBH Effective date: 20221221 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2024 BY PAVIS PAYMENTS GMBH Effective date: 20231214 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 DEC 2025 BY PAVIS PAYMENT GMBH Effective date: 20241216 |